Healthcare / BiotechnologyNasdaqCM
$3.56
-0.02 (-0.56%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $64.5M · quality 50.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
57/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$530M
P/E
17.8x
↓EV/EBITDA
4.9x
↓ROE
18.9%
↑Gross Margin
82.6%
↑Debt/Equity
0.07
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2010–2025 · 15 años de histórico normalizado
Revenue CAGR
+51.9%
FCF CAGR
—
FCF margin
17.4%
FCF / Net income
1.50x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $418.6M · net income $48.6M · FCF $73.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||||||
| Revenue | $418.6M | $418.6M | $348.9M | $321.5M | $267.8M | $242.0M | $248.2M | $299.3M | $359.1M | $321.1M | $221.7M | — | — | — | — | $7.8M | $788874.00 |
| Net Income | $48.6M | $48.6M | $42.4M | $58.2M | $-30.2M | $-10.3M | $-49.3M | $-25.6M | $-30.0M | $64.7M | $390000.00 | $29.4M | $6.2M | $-4.1M | $-7.7M | $-10.2M | $-11.4M |
| EBITDA | $78.8M | $78.8M | $65.4M | $40.5M | $-10.7M | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS | 0.32 | 0.32 | 0.28 | 0.37 | -0.33 | -0.15 | -0.77 | -0.24 | -0.28 | 0.56 | 0.00 | 0.26 | 0.05 | -0.04 | -0.09 | — | — |
| Gross Margin | 82.6% | 82.6% | 82.8% | 83.0% | 82.0% | 83.6% | 84.2% | 85.6% | 89.9% | 89.0% | 86.0% | — | — | — | — | 56.7% | — |
| Operating Margin | 15.3% | 15.3% | 17.0% | 11.5% | -5.5% | -2.9% | -18.3% | -7.1% | -1.1% | 14.4% | 0.4% | — | — | — | — | -125.8% | -1335.2% |
| Net Margin | 11.6% | 11.6% | 12.2% | 18.1% | -11.3% | -4.2% | -19.9% | -8.5% | -8.3% | 20.2% | 0.2% | — | — | — | — | -131.4% | -1447.6% |
| Balance Sheet | |||||||||||||||||
| Debt/Equity | 0.07 | 0.07 | 0.10 | 0.34 | -2.70 | 586.91 | -317.98 | 1.80 | 0.00 | — | — | — | — | 0.00 | 0.20 | 0.23 | — |
| Current Ratio | 5.39 | 5.39 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||||||||
| Free Cash Flow | $73.0M | $73.0M | $64.5M | $24.8M | $-19.4M | $-5.2M | — | — | — | — | — | — | — | — | — | — | — |
| Returns | |||||||||||||||||
| ROE | 18.9% | 18.9% | 22.0% | 40.8% | 167.9% | -12542.7% | 32856.0% | -74.4% | -60.4% | 87.7% | 0.8% | 84.8% | 7.0% | -5.6% | -38.3% | -85.7% | -187.2% |
| Valuation | |||||||||||||||||
| P/E | 17.80 | 17.80 | 32.82 | 21.08 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EV/EBITDA | 4.89 | 4.89 | 19.65 | 27.27 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| P/B | 2.08 | 2.08 | 7.09 | 7.98 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | |||||||||||||||||
| Revenue Growth | 20.0% | 20.0% | 8.5% | 20.0% | — | -2.5% | -17.0% | -16.7% | 11.8% | 44.8% | — | — | — | — | — | 883.7% | — |
| EPS Growth | 14.3% | 14.3% | -24.3% | 212.1% | — | 80.5% | -220.8% | 14.3% | -150.0% | — | -100.0% | 420.0% | 225.0% | 55.6% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-0.4%
EPS terminal req.
$0.32
Spread vs growth
14.7%
5Y implied EPS CAGR
3.6%
EPS terminal req.
$0.38
Spread vs growth
10.7%
10Y implied EPS CAGR
6.8%
EPS terminal req.
$0.62
Spread vs growth
7.5%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-44.3%
Start / end P/E
22.8x → 11.1x
EPS bridge
0.28 → 0.32
Residual
-7.3%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.